Stock AUTL AUTOLUS THERAPEUTICS PLC
Add to a list
To use this feature you must be a member
Log inSign up

All News Autolus Therapeutics plc

Equities

AUTL

US05280R1005

Market Closed - Nasdaq
Other stock markets
 16:00:00 2024-05-08 EDT 		5-day change 1st Jan Change
4.11 USD +2.49% Intraday chart for Autolus Therapeutics plc +2.75% -36.18%
05-08 European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Wednesday Trading MT
05-03 European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Set to Close Week Lower MT

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Wednesday Trading
MT
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Set to Close Week Lower
MT
European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Thursday Trading
MT
Abstract for longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL selected for an oral presentation at ASCO
GL
Autolus Therapeutics to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024
GL
European Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading But End Week Down
MT
European Equities Traded in the US as American Depositary Receipts Flat in Thursday Trading
MT
European Equities Traded in the US as American Depositary Receipts Decline in Thursday Trading
MT
European Equities Traded in the US as American Depositary Receipts Open Week Higher in Monday Trading
MT
European Equities Close Lower Tuesday; Eurozone Manufacturing at 3-Month Low; Mining Stocks Rally, Real Estate Drops
MT
European Equities Traded in the US as American Depositary Receipts Fall in Tuesday Trading
MT
Autolus Therapeutics Gets European Agency Approval for Marketing Authorization Application for Leukemia Treatment
MT
Autolus Therapeutics announces acceptance of Marketing Authorization Application (MAA) by the European Medicines Agency (EMA) for obecabtagene autoleucel (obe-cel) for Patients with Relapsed/refractory (r/r) Adult B-Cell Acute Lymphoblastic Leukemia (B-ALL)
GL
Autolus Therapeutics announces acceptance of Marketing Authorization Application (MAA) by the European Medicines Agency (EMA) for obecabtagene autoleucel (obe-cel) for Patients with Relapsed/refractory (r/r) Adult B-Cell Acute Lymphoblastic Leukemia (B-ALL)
AQ
Autolus Therapeutics Announces Acceptance of Marketing Authorization Application by the European Medicines Agency for obecabtagene autoleucel (obe-cel) for Patients with Relapsed/refractory (r/r) Adult B-Cell Acute Lymphoblastic Leukemia (B-ALL)
CI
EARNINGS: EPE Special "cautiously optimistic"; RTW Biotech NAV rises
AN
Autolus Therapeutics Appoints Mike Bonney as Chair
MT
European Equities Traded in the US as American Depositary Receipts Start Week Modestly Higher
MT
Autolus Therapeutics Announces Changes to its Board of Directors
GL
Autolus Therapeutics Announces Changes to its Board of Directors
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. AUTL Stock
  4. News Autolus Therapeutics plc
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW